Figure 7 | Scientific Reports

Figure 7

From: Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response

Figure 7

Schematic of the multiple mechanisms of action (MOA) for PDL1/LAG3/TIGIT multispecific antibodies. GB265, GB266, and GB266T antibodies engage T cells with cancer cells and APCs through Fc-FcgR interaction and antibody binding to target molecules PD-L1, LAG-3, and TIGIT, and block these major immune checkpoint pathways. All these MOAs work in concert to enhance T cell activation and tumor cell killing. Created with BioRender.com.

Back to article page